Shares of Celsion Corporation (NASDAQ:CLSN) fell 3.2% on Monday . The company traded as low as $2.25 and last traded at $2.24. 838,108 shares were traded during trading, a decline of 74% from the average session volume of 3,228,840 shares. The stock had previously closed at $2.31.

A number of research firms have weighed in on CLSN. Maxim Group reaffirmed a “hold” rating on shares of Celsion Corporation in a research note on Tuesday, August 15th. Zacks Investment Research cut shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $12.63.

The firm’s market cap is $18.87 million. The firm has a 50 day moving average of $2.78 and a 200 day moving average of $1.76.

An institutional investor recently raised its position in Celsion Corporation stock. Renaissance Technologies LLC increased its holdings in Celsion Corporation (NASDAQ:CLSN) by 100.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,375,147 shares of the biotechnology company’s stock after purchasing an additional 690,349 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Celsion Corporation worth $397,000 as of its most recent filing with the Securities & Exchange Commission. 7.46% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at

Celsion Corporation Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.